Orlistat-associated adverse effects and drug interactions: A critical review

Drug Safety

Volumn 31, Issue 1, 2008, Pages 53-65

  Filippatos, Theodosios D ^a   Derdemezis, Christos S ^a   Gazi, Irene F ^a   Nakou, Eleni S ^a   Mikhailidis, Dimitri P ^b   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Alcohol, drug interactions; Amiodarone, drug interactions; Antiepileptic drugs, drug interactions; Antihyperglycaemics, drug interactions; Antipsychotics, drug interactions; Ciclosporin, drug interactions; Contraceptives, drug interactions

Indexed keywords

ALCOHOL; ALPHA TOCOPHEROL; AMIODARONE; ANTIDIABETIC AGENT; BETA CAROTENE; CENTRAL NERVOUS SYSTEM AGENTS; CYANOCOBALAMIN; CYCLOSPORIN A; FOLIC ACID; GABAPENTIN; GLIBENCLAMIDE; LAMOTRIGINE; LOPERAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; ORAL CONTRACEPTIVE AGENT; OXALIC ACID; PLACEBO; PSYLLIUM HYDROCOLLOID; RETINOL; SIBUTRAMINE; SUCROSE POLYESTER; TETRAHYDROLIPSTATIN; THYROXINE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; VITAMIN D; VITAMIN K GROUP; WARFARIN;

ABDOMINAL PAIN; ABNORMAL FECES; ANUS FISSURE; BLOOD PRESSURE REGULATION; BONE METABOLISM; BONE TURNOVER; CALCIUM METABOLISM; CANCER RISK; CARBOHYDRATE METABOLISM; CHOLELITHIASIS; CHOLOSTATIC HEPATITIS; CLINICAL TRIAL; CONSTIPATION; COPPER METABOLISM; DEFECATION URGENCY; DEPRESSION; DIABETIC KETOACIDOSIS; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG WITHDRAWAL; FECAL SPOTTING; FECES INCONTINENCE; FLATULENCE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEART RATE; HEPATITIS; HUMAN; HYPEROXALURIA; HYPERTENSION; HYPOTHYROIDISM; IRON METABOLISM; KIDNEY FAILURE; KIDNEY INJURY; LASSITUDE; LEG EDEMA; LEUKOCYTOCLASTIC VASCULITIS; LICHENOID; LICHENOID ERUPTION; LIPID METABOLISM; LIVER FAILURE; LIVER INJURY; LIVER NECROSIS; MAGNESIUM METABOLISM; MALABSORPTION; MALAISE; MEMORY DISORDER; NEPHROTOXICITY; NONHUMAN; OBESITY; OILY STOOL; PANCREATITIS; PHOSPHATE METABOLISM; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SUBACUTE LIVER FAILURE; SUBCUTANEOUS TISSUE; VAGINITIS; VULVITIS; WEIGHT REDUCTION; ZINC METABOLISM;

EID: 37549037023     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831010-00005     Document Type: Review

References (137)

1. Dahlin A, Beermann B. Incorrect use of orlistat and sibutramine in clinical practice. Eur J Clin Pharmacol 2007 Feb; 63 (2): 205-9
2. Carriere F, Renou C, Ransac S, et al. Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2001 Jul; 281 (1): G16-28
3. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997 Jun; 21 Suppl. 3: S12-23
4. Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994 Jul; 56 (1): 82-5
5. Zhi J, Melia AT, Eggers H, et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol 1995 Nov; 35 (11): 1103-8
6. Zhi J, Melia AT, Funk C, et al. Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. J Clin Pharmacol 1996 Nov; 36 (11): 1006-11
7. Zhi J, Mulligan TE, Hauptman JB. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. J Clin Pharmacol 1999 Jan; 39 (1): 41-6
8. US Food and Drug Administration. FDA approves orlistat for over-the-counter use [online]. Available from URL: http://www.fda.gov/bbs/ topics/NEWS/2007/new01557.html [Accessed 2007 Oct 15]
9. Toplak H, Ziegler O, Keller U, et al. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. Diabetes Obes Metab 2005 Nov; 7 (6): 699-708
10. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004 Jan; 27 (1): 155-61
11. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2002 Nov; 4 (6): 415-23
12. Didangelos TP, Thanopoulou AK, Bousboulas SH, et al. The ORLIstat and Cardiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study. Curr Med Res Opin 2004 Sep; 20 (9): 1393-401
13. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999 Jan 20; 281 (3): 235-42
14. Chanoine JP, Hampl S, Jensen C, et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005 Jun 15; 293 (23): 2873-83
15. O'Meara S, Riemsma R, Shirran L, et al. A systematic review of the clinical effectiveness of orlistat used for the management of obesity. Obes Rev 2004 Feb; 5 (1): 51-68
16. O'Meara S, Riemsma R, Shirran L, et al. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. Health Technol Assess 2001; 5 (18): 1-81
17. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998 Jul 18; 352 (9123): 167-72
18. Van Gaal LF, Broom JI, Enzi G, et al. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. Eur J Clin Pharmacol 1998 Apr; 54 (2): 125-32
19. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 2003 Dec; 27 (12): 1437-46
20. Canovatchel W. Long-term tolerability profile of orlistat, an intestinal lipase inhibitor [abstract]. 16th International Diabetes Federation Congress; 1997 Jul 25-27, Helsinki
21. Kiortsis DN, Filippatos TD, Elisaf MS. The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab 2005 Feb; 31 (1): 15-22
22. Napier S, Thomas M. 36 year old man presenting with pancreatitis and a history of recent commencement of orlistat: case report. Nutr J 2006; 5: 19
23. Froehlich F, Hartmann D, Guezelhan C, et al. Influence of orlistat on the regulation of gallbladder contraction in man: a randomized double-blind placebo-controlled crossover study. Dig Dis Sci 1996 Dec; 41 (12): 2404-8
24. Richelsen B, Tonstad S, Rossner S, et al. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care 2007 Jan; 30 (1): 27-32
25. Kim DH, Lee EH, Hwang JC, et al. A case of acute cholestatic hepatitis associated with orlistat [in Korean] [abstract]. Taehan Kan Hakhoe Chi 2002 Sep; 8 (3): 317-20
26. Montero JL, Muntane J, Fraga E, et al. Orlistat associated subacute hepatic failure. J Hepatol 2001 Jan; 34 (1): 173
27. Thurairajah PH, Syn WK, Neil DA, et al. Orlistat (Xenical)-induced subacute liver failure. Eur J Gastroenterol Hepatol 2005 Dec; 17 (12): 1437-8
28. Lau G, Chan CL. Massive hepatocellular [correction of hepatocullular] necrosis: was it caused by orlistat? Med Sci Law 2002 Oct; 42 (4): 309-12
29. Umemura T, Ichijo T, Matsumoto A, et al. Severe hepatic injury caused by orlistat. Am J Med 2006 Aug; 119 (8): e7
30. Diakou MC, Liberopoulos EN, Mikhailidis DP, et al. Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence. Scand J Gastroenterol 2007 Feb; 42 (2): 139-47
31. Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006 May; 22 (5): 873-83
32. Harrison SA, Fincke C, Helinski D, et al. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004 Sep 15; 20 (6): 623-8
33. Zelber-Sagi S, Kessler A, Brazowsky E, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of _yclosporine_ fatty liver disease. Clin Gastroenterol Hepatol 2006 May; 4 (5): 639-44
34. Caner M, Dogruman H, Taskin E, et al. Effects of orlistat and its relationship with nitric oxide in the small intestinal mucosa. Chin J Physiol 2005 Dec 31; 48 (4): 217-22
35. O'Donovan D, Horowitz M, Russo A, et al. Effects of lipase inhibition on gastric emptying of, and on the glycaemic, insulin and cardiovascular responses to, a high-fat/carbohydrate meal in type 2 diabetes. Diabetologia 2004 Dec; 47 (12): 2208-14
36. Pilichiewicz A, O'Donovan D, Feinle C, et al. Effect of lipase inhibition on gastric emptying of, and the glycemic and incretin responses to, an oil/aqueous drink in type 2 diabetes mellitus. J Clin Endocrinol Metab 2003 Aug; 88 (8): 3829-34
37. Goedecke JH, Barsdorf M, Beglinger C, et al. Effects of a lipase inhibitor (orlistat) on cholecystokinin and appetite in response to a high-fat meal. Int J Obes Relat Metab Disord 2003 Dec; 27 (12): 1479-85
38. Fox M, Thumshirn M, Menne D, et al. The pathophysiology of faecal spotting in obese subjects during treatment with orlistat. Aliment Pharmacol Ther 2004 Feb 1; 19 (3): 311-21
39. Heck AM, Calis KA, McDuffie JR, et al. Additive gastrointestinal effects with concomitant use of olestra and orlistat. Ann Pharmacother 2002 Jun; 36 (6): 1003-5
40. Cavaliere H, Floriano I, Medeiros-Neto G. Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid). Int J Obes Relat Metab Disord 2001 Jul; 25 (7): 1095-9
41. Fox M, Stutz B, Menne D, et al. The effects of loperamide on continence problems and anorectal function in obese subjects taking orlistat. Dig Dis Sci 2005 Sep; 50 (9): 1576-83
42. Guarino AH. Treatment of intractable constipation with orlistat: a report of three cases. Pain Med 2005 Jul-Aug; 6 (4): 327-8
43. Sharma AM, Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 2002 Sep; 20 (9): 1873-8
44. Derosa G, Cicero AF, Murdolo G, et al. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab 2005 Jan; 7 (1): 47-55
45. Bakris G, Calhoun D, Egan B, et al. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens 2002 Nov; 20 (11): 2257-67
46. Avenell A, Broom J, Brown TJ, et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004 May; 8 (21): iii-iv, 1-182
47. Zavoral JH. Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertens. 1998 Dec; 16 (12 Pt 2): 2013-7
48. Schneider R, Golzman B, Turkot S, et al. Effect of weight loss on blood pressure, arterial compliance, and insulin resistance in normotensive obese subjects. Am J Med Sci 2005 Oct; 330 (4): 157-60
49. Filippatos TD, Gazi IF, Liberopoulos EN, et al. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A (2) in obese patients with metabolic syndrome. Atherosclerosis 2007; 193 (2): 428-37
50. Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin 2005 Dec; 21 (12): 1997-2006
51. Zanella MT, Uehara MH, Ribeiro AB, et al. Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study. Arq Bras Endocrinol Metabol 2006 Apr; 50 (2): 368-76
52. Reaven G, Segal K, Hauptman J, et al. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol 2001 Apr 1; 87 (7): 827-31
53. Halpern A, Mancini MC, Suplicy H, et al. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes Obes Metab 2003 May; 5 (3): 180-8
54. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998 Aug; 21 (8): 1288-94
55. Broom I, Wilding J, Stott P, et al. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. Int J Clin Pract 2002 Sep; 56 (7): 494-9
56. Derosa G, Cicero AF, Murdolo G, et al. Comparison of metabolic effects of orlistat and sibutramine treatment in type 2 diabetic obese patients. Diabetes Nutr Metab 2004 Aug; 17 (4): 222-9
57. Bloch KV, Salles GF, Muxfeldt ES, et al. Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial. J Hypertens 2003 Nov; 21 (11): 2159-65
58. Tong PC, Lee ZS, Sea MM, et al. The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes. Arch Intern Med 2002 Nov 25; 162 (21): 2428-35
59. Kuo CS, Pei D, Yao CY, et al. Effect of orlistat in overweight poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study. Int J Clin Pract 2006 Aug; 60 (8): 906-10
60. Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005 Mar; 21 (3): 457-68
61. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007 Jan 6; 369 (9555): 71-7
62. Persson M, Vitols S, Yue QY. Orlistat associated with hypertension [letter]. BMJ 2000 Jul 8; 321 (7253): 87
63. Johnston GD. Orlistat associated with hypertension: digit preference lays conclusions about orlistat open to doubt [letter]. BMJ 2001 Jan 13; 322 (7278): 110
64. Huber MH. Orlistat associated with hypertension: Roche concludes that there is not evidence of a casual association. BMJ 2001 Jan 13; 322 (7278): 110-1
65. Patten SB. Major depressive episodes and diet pills. Expert Opin Pharmacother 2002 Oct; 3 (10): 1405-9
66. Benazzi F. Depression induced by orlistat (Xenical) [letter]. Can J Psychiatry 2000 Feb; 45 (1): 87
67. Kiortsis DN, Tsouli S, Filippatos TD, et al. Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomized study. Nutr Metab Cardiovasc Dis. In press
68. Golay A, Laurent-Jaccard A, Habicht F, et al. Effect of orlistat in obese patients with binge eating disorder. Obes Res 2005 Oct; 13 (10): 1701-8
69. heleritis CG, Papadimitriou GN, Papageorgiou CC, et al. Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report. BMC Psychiatry 2006; 6: 37
70. Fernandez-Aranda F, Amor A, Jimenez-Murcia S, et al. Bulimia nervosa and misuse of orlistat: two case reports. Int J Eat Disord 2001 Dec; 30 (4): 458-61
71. Kaya A, Aydin N, Topsever P, et al. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. Biomed Pharmacother 2004 Dec; 58 (10): 582-7
72. Acharya NV, Wilton LV, Shakir SA. Safety profile of orlistat: results of a prescription-event monitoring study. Int J Obes 2006; 30: 1645-52
73. Pritchard JE, Nowson CA, Wark JD. Bone loss accompanying diet-induced or exercise-induced weight loss: a randomised controlled study. Int J Obes Relat Metab Disord 1996 Jun; 20 (6): 513-20
74. Pace DG, Blotner S, Guerciolini R. Short-term orlistat treatment does not affect mineral balance and bone turnover in obese men. J Nutr 2001 Jun; 131 (6): 1694-9
75. Zhi J, Moore R, Kanitra L. The effect of short-term (21-day) orlistat treatment on the physiologic balance of six selected macrominerals and microminerals in obese adolescents. J Am Coll Nutr 2003 Oct; 22 (5): 357-62
76. Gotfredsen A, Westergren Hendel H, Andersen T. Influence of orlistat on bone turnover and body composition. Int J Obes Relat Metab Disord 2001 Aug; 25 (8): 1154-60
77. Ferraz RR, Tiselius HG, Heilberg IP. Fat malabsorption induced by gastrointestinal lipase inhibitor leads to an increase in urinary oxalate excretion. Kidney Int 2004 Aug; 66 (2): 676-82
78. Singh A, Sarkar SR, Gaber LW, et al. Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor. Am J Kidney Dis 2007 Jan; 49 (1): 153-7
79. Courtney AE, O'Rourke DM, Maxwell AP. Rapidly progressive renal failure associated with successful pharmacotherapy for obesity. Nephrol Dial Transplant 2007 Feb; 22 (2): 621-3
80. Packard KA, Wurdeman RL, Reyes AP. Constipation, polyuria, polydipsia, and edema associated with orlistat. Ann Pharmacother 2002 Jul-Aug; 36 (7-8): 1168-70
81. Rowe R, Cowx M, Poole C, et al. The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss. Curr Med Res Opin 2005 Nov; 21 (11): 1885-90
82. Liberopoulos EN, Tsouli S, Mikhailidis DP, et al. Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets 2006 Feb; 7 (2): 211-28
83. Berne C. A randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin. Diabet Med 2005 May; 22 (5): 612-8
84. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002 Jul; 25 (7): 1123-8
85. Xenical® (orlistat) capsules [prescribing information]. Revised 2003 Dec. Roche Laboratories Inc. [online]. Available from URL: http://www.fda.gov/ medwatch/SAFETY/2003/03DEC_PI/Xenical_PI.pdf [Accessed 2007 Oct 15]
86. Bergholm R, Tiikkainen M, Vehkavaara S, et al. Lowering of LDL cholesterol rather than moderate weight loss improves endothelium-dependent vasodilatation in obese women with previous gestational diabetes. Diabetes Care 2003 Jun; 26 (6): 1667-72
87. Diamanti-Kandarakis E, Katsikis I, Piperi C, et al. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007 Jan; 66 (1): 103-9
88. Diamanti-Kandarakis E, Piperi C, Alexandraki K, et al. Short-term effect of orlistat on dietary glycotoxins in healthy women and women with polycystic ovary syndrome. Metabolism 2006 Apr; 55 (4): 494-500
89. Czerwienska B, Kokot F, Franek E, et al. Effect of orlistat therapy on carbohydrate, lipid, vitamin and hormone plasma levels in obese subjects [in Polish]. Pol Arch Med Wewn 2004 Dec; 112 (6): 1415-23
90. Paraskevas KI, Liapis CD, Mikhailidis DP. Leptin: a promising therapeutic target with pleiotropic action besides body weight regulation. Curr Drug Targets 2006 Jun; 7 (6): 761-71
91. Jayagopal V, Kilpatrick ES, Holding S, et al. Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. J Clin Endocrinol Metab 2005 Feb; 90 (2): 729-33
92. Damci T, Yalin S, Balci H, et al. Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients. Diabetes Care 2004 May; 27 (5): 1077-80
93. Azar ST, Zantout MS. Diabetic ketoacidosis associated with orlistat treatment [letter]. Diabetes Care 2001 Mar; 24 (3): 602
94. Gonzalez-Gay MA, Garcia-Porrua C, Lueiro M, et al. Orlistat-induced cutaneous leukocytoclastic vasculitis [letter]. Arthritis Rheum 2002 Oct 15; 47 (5): 567
95. Sergeant A, Milne G, Shaffrali F. Lichenoid eruption associated with orlistat. Br J Dermatol 2006 May; 154 (5): 1020-1
96. Morotomi M, Sakaitani Y, Satou M, et al. Effects of a high-fat diet on azoxymethane-induced aberrant crypt foci and fecal biochemistry and microbial activity in rats. Nutr Cancer 1997; 27 (1): 84-91
97. Newmark HL, Yang K, Lipkin M, et al. A Western-style diet induces benign and malignant neoplasms in the colon of normal C57Bl/6 mice. Carcinogenesis 2001 Nov; 22 (11): 1871-5
98. Thornton Jr WH, MacDonald RS. Dietary fat quantity and composition induce changes in proliferation and membrane lipids in rat colon cells. Ann Nutr Metab 1997; 41 (4): 260-8
99. Garcia SB, Barros LT, Turatti A, et al. The anti-obesity agent orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen. Cancer Lett 2006 Aug 28; 240 (2): 221-4
100. Kridel SJ, Axelrod F, Rozenkrantz N, et al. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 2004 Mar 15; 64 (6): 2070-5
101. Menendez JA, Vellon L, Lupu R. Orlistat: from antiobesity drug to anticancer agent in Her-2/neu (erbB-2)-overexpressing gastrointestinal tumors? Exp Biol Med (Maywood) 2005 Mar; 230 (3): 151-4
102. Browne CD, Hindmarsh EJ, Smith JW. Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor. FASEB J 2006 Oct; 20 (12): 2027-35
103. Menendez JA, Vellon L, Lupu R. The antiobesity drug orlistat induces cytotoxic effects, suppresses Her-2/neu (erbB-2) oncogene overexpression, and synergistically interacts with trastuzumab (Herceptin) in chemoresistant ovarian cancer cells. Int J Gynecol Cancer 2006 Jan-Feb; 16 (1): 219-21
104. Menendez JA, Vellon L, Lupu R. Antitumoral actions of the anti-obesity drug orlistat (Xenical™) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Ann Oncol 2005 Aug; 16 (8): 1253-67
105. Lupu R, Menendez JA. Pharmacological inhibitors of Fatty Acid Synthase (FASN): catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? Curr Pharm Biotechnol 2006 Dec; 7 (6): 483-93
106. Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol 1996 Jul; 36 (7): 647-53
107. Zhi J, Melia AT, Koss-Twardy SG, et al. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers. J Clin Pharmacol 1996 Feb; 36 (2): 152-9
108. McDuffie JR, Calis KA, Booth SL, et al. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy 2002 Jul; 22 (7): 814-22
109. Holecki M, Zahorska-Markiewicz B, Nieszporek T, et al. The influence of a 3-month weight reduction therapy with orlistat on serum vitamin B12 and folic acid concentration in obese women. Int J Obes (Lond) 2006 Jun; 30 (6): 1017-8
110. Zhi J, Melia AT, Guerciolini R, et al. The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol 1996 Jul; 36 (7): 659-66
111. MacWalter RS, Fraser HW, Armstrong KM. Orlistat enhances warfarin effect. Ann Pharmacother 2003 Apr; 37 (4): 510-2
112. Zhi J, Moore R, Kanitra L, et al. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. J Clin Pharmacol. 2003 Apr; 43 (4): 428-35
113. Le Beller C, Bezie Y, Chabatte C, et al. Co-administration of orlistat and cyclosporine in a heart transplant recipient. Transplantation 2000 Nov 27; 70 (10): 1541-2
114. Evans S, Michael R, Wells H, et al. Drug interaction in a renal transplant patient: cyclosporine-neoral and orlistat. Am J Kidney Dis 2003 Feb; 41 (2): 493-6
115. Nagele H, Petersen B, Bonacker U, et al. Effect of orlistat on blood cyclosporine concentration in an obese heart transplant patient. Eur J Clin Pharmacol 1999 Nov; 55 (9): 667-9
116. Asberg A. Interactions between cyclosporine and lipid-lowering drugs: implications for organ transplant recipients. Drugs 2003; 63 (4): 367-78
117. Barbaro D, Orsini P, Pallini S, et al. Obesity in transplant patients: case report showing interference of orlistat with absorption of cyclosporine and review of literature. Endocr Pract 2002 Mar-Apr; 8 (2): 124-6
118. Schnetzler B, Kondo-Oestreicher M, Vala D, et al. Orlistat decreases the plasma level of cyclosporine and may be responsible for the development of acute rejection episodes. Transplantation 2000 Nov 27; 70 (10): 1540-1
119. Zhi J, Moore R, Kanitra L, et al. Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. J Clin Pharmacol 2002 Sep; 42 (9): 1011-9
120. Errasti P, Garcia I, Lavilla J, et al. Reduction in blood cyclosporine concentration by orlistat in two renal transplant patients. Transplant Proc 2002 Feb; 34 (1): 137-9
121. Colman E, Fossler M. Reduction in blood cyclosporine concentrations by orlistat. N Engl J Med 2000 Apr 13; 342 (15): 1141-2
122. Bigham S, McGuigan C, MacDonald BK. Reduced absorption of lipophilic anti-epileptic medications when used concomitantly with the anti-obesity drug orlistat [letter]. Epilepsia 2006 Dec; 47 (12): 2207
123. Hilger E, Quiner S, Ginzel I, et al. The effect of orlistat on plasma levels of psychotropic drugs in patients with long-term psychopharmacotherapy. J Clin Psychopharmacol 2002 Feb; 22 (1): 68-70
124. Pavlovic ZM. Orlistat in the treatment of clozapine-induced hyperglycemia and weight gain [letter]. Eur Psychiatry 2005 Nov; 20 (7): 520
125. Peleg R. Caution when using oral contraceptive pills with Orlistat [letter]. Isr Med Assoc J 2000 Sep; 2 (9): 712
126. Hartmann D, Guzelhan C, Zuiderwijk PB, et al. Lack of interaction between orlistat and oral contraceptives. Eur J Clin Pharmacol 1996; 50 (5): 421-4
127. Madhava K, Hartley A. Hypothyroidism in thyroid carcinoma follow-up: orlistat may inhibit the absorption of thyroxine [letter]. Clin Oncol (R Coll Radiol) 2005 Sep; 17 (6): 492
128. Chaikomin R, Russo A, Rayner CK, et al. Effects of lipase inhibition on gastric emptying and alcohol absorption in healthy subjects. Br J Nutr 2006 Nov; 96 (5): 883-7
129. Melia AT, Zhi J, Zelasko R, et al. The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers. Eur J Clin Pharmacol 1998 Nov-Dec; 54 (9-10): 773-7
130. Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002 Jun; 25 (6): 1033-41
131. Pathan MF, Latif ZA, Nazneen NE, et al. Orlistat as an adjunct therapy in type 2 obese diabetic patients treated with sulphonylurea: a Bangladesh experience. Bangladesh Med Res Counc Bull 2004 Apr; 30 (1): 1-8
132. Sari R, Balci MK, Coban E, et al. Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women. Int J Obes Relat Metab Disord 2004 Aug; 28 (8): 1059-63
133. Zhi J, Melia AT, Koss-Twardy SG, et al. The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers. J Clin Pharmacol 1995 May; 35 (5): 521-5
134. Melia AT, Mulligan TE, Zhi J. The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers. J Clin Pharmacol 1996 Jul; 36 (7): 654-8
135. Weber C, Tam YK, Schmidtke-Schrezenmeier G, et al. Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers. Eur J Clin Pharmacol 1996; 51 (1): 87-90
136. Melia AT, Mulligan TE, Zhi J. Lack of effect of orlistat on the bioavailability of a single dose of nifedipine extended-release tablets (Procardia XL) in healthy volunteers. J Clin Pharmacol 1996 Apr; 36 (4): 352-5
137. Derosa G, Mugellini A, Ciccarelli L, et al. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Ther 2003 Apr; 25 (4): 1107-22